Production of a chikungunya vaccine using a CHO cell and attenuated viral-based platform technology

Simple item page
dc.contributor.authorEldi, P.
dc.contributor.authorCooper, T.
dc.contributor.authorLiu, L.
dc.contributor.authorProw, N.
dc.contributor.authorDiener, K.
dc.contributor.authorHowley, P.
dc.contributor.authorSuhrbier, A.
dc.contributor.authorHayball, J.
dc.date.issued2017
dc.description.abstractVaccinia-based systems have been extensively explored for the development of recombinant vaccines. Herein we describe an innovative vaccinia virus (VACV)-derived vaccine platform technology termed Sementis Copenhagen Vector (SCV), which was rendered multiplication-defective by targeted deletion of the essential viral assembly gene D13L. A SCV cell substrate line was developed for SCV vaccine production by engineering CHO cells to express D13 and the VACV host-range factor CP77, because CHO cells are routinely used for manufacture of biologics. To illustrate the utility of the platform technology, a SCV vaccine against chikungunya virus (SCV-CHIK) was developed and shown to be multiplication-defective in a range of human cell lines and in immunocompromised mice. A single vaccination of mice with SCV-CHIK induced antibody responses specific for chikungunya virus (CHIKV) that were similar to those raised following vaccination with a replication-competent VACV-CHIK and able to neutralize CHIKV. Vaccination also provided protection against CHIKV challenge, preventing both viremia and arthritis. Moreover, SCV retained capacity as an effective mouse smallpox vaccine. In summary, SCV represents a new and safe vaccine platform technology that can be manufactured in modified CHO cells, with pre-clinical evaluation illustrating utility for CHIKV vaccine design and construction.
dc.description.statementofresponsibilityPreethi Eldi, Tamara H. Cooper, Liang Liu, Natalie A. Prow, Kerrilyn R. Diener, Paul M. Howley, Andreas Suhrbier, and John D. Hayball
dc.identifier.citationMolecular Therapy, 2017; 25(10):2332-2344
dc.identifier.doi10.1016/j.ymthe.2017.06.017
dc.identifier.issn1525-0016
dc.identifier.issn1525-0024
dc.identifier.orcidDiener, K. [0000-0001-8417-5542]
dc.identifier.orcidHayball, J. [0000-0002-3089-4506]
dc.identifier.urihttps://hdl.handle.net/2440/132324
dc.language.isoen
dc.publisherElsevier; American Society of Gene and Cell Therapy
dc.relation.granthttp://purl.org/au-research/grants/arc/LP160100633
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1012386
dc.rights© 2017 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.source.urihttps://doi.org/10.1016/j.ymthe.2017.06.017
dc.subjectVaccine; chikungunya; vaccinia virus; live vectored vaccines; poxvirus; antibody; vaccine platform
dc.subject.meshCHO Cells
dc.subject.meshAnimals
dc.subject.meshCricetulus
dc.subject.meshVaccinia virus
dc.subject.meshChikungunya virus
dc.subject.meshViral Vaccines
dc.subject.meshAntibodies, Viral
dc.subject.meshAntibodies, Neutralizing
dc.subject.meshChikungunya Fever
dc.titleProduction of a chikungunya vaccine using a CHO cell and attenuated viral-based platform technology
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_132324.pdf
Size:
1.79 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Microbiology and Immunology publications